SCHEMBL10112381

SCHEMBL10112381

COC(=O)c1ccc(-c2c3ccccc3c(-c3ccc(C(=O)OC)cc3)c3c(N(c4ccccc4)c4ccc(N(c5ccccc5)c5ccccc5)cc4)cccc23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 1/20 0.41
TNKS O95271 2/20 0.40
PTPN1 P18031 1/20 0.40
MAPK1 P28482 2/20 0.39
GPR84 Q9NQS5 1/20 0.39
EGFR P00533 1/20 0.39
ROCK2 O75116 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.38
MAPT P10636 5/20 0.38
RAB9A P51151 3/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
PDE5A O76074 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10112618 0.89 ALDH1A1 (0.41) MEN1KMT2ATNKSEGFRMAPT
SCHEMBL10112385 0.89 GABRG2 (0.41) MEN1KMT2ATSHRGPR84RAB9A
SCHEMBL10112371 0.88 TTR (0.42) TSHRTNKSEGFR
SCHEMBL10112493 0.85 PTGER4 (0.38) MAPTALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL10129322 0.83 HPGD (0.38) MEN1KMT2ATSHRL3MBTL1MAPT
SCHEMBL10112382 0.83 TSHR (0.45) MEN1KMT2ATSHRTNKSPTPN1
SCHEMBL10112392 0.82 ACHE (0.40) EGFRMAPTRAB9AALDH1A1HPGD
SCHEMBL8406139 0.81 ALDH1A1 (0.35) MEN1KMT2AL3MBTL1MAPTALDH1A1
SCHEMBL8406124 0.81 ALDH1A1 (0.37) MEN1KMT2ATSHRMAPK1L3MBTL1
SCHEMBL13615833 0.81 ALDH1A1 (0.39) MEN1KMT2AL3MBTL1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110980-B2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-07 US disclosed
US-20100164376-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2010-07-01 US disclosed
US-7674914-B2 novel anthracene derivative represented by General Formula (1) is provided, which enables the production of a light-emitting element with high luminous efficiency and a long lifetime. A high-performance light-emitting device and electronic device in which the anthracene derivative light emitting diode SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2010-03-09 US disclosed
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative AMY1A, CYP1A1, CRY1 MEN1 711/4885KMT2A 3491/4885TSHR 4186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.